• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non-Small Cell Lung Cancer Treated with Nivolumab.

作者信息

Funazo Tomoko, Nomizo Takashi, Kim Young Hak

机构信息

Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

出版信息

J Thorac Oncol. 2017 Sep;12(9):e140-e141. doi: 10.1016/j.jtho.2017.04.027.

DOI:10.1016/j.jtho.2017.04.027
PMID:28838713
Abstract
摘要

相似文献

1
Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non-Small Cell Lung Cancer Treated with Nivolumab.肝转移与接受纳武利尤单抗治疗的非小细胞肺癌患者的无进展生存期较差相关。
J Thorac Oncol. 2017 Sep;12(9):e140-e141. doi: 10.1016/j.jtho.2017.04.027.
2
Nivolumab (Opdivo°) and metastatic or inoperable lung cancer.纳武单抗（欧狄沃°）与转移性或不可切除的肺癌
Prescrire Int. 2017 Apr;26(181):93-94.
3
Nivolumab improves survival for patients with advanced lung cancer.纳武单抗可提高晚期肺癌患者的生存率。
Cancer. 2017 Sep 1;123(17):3211. doi: 10.1002/cncr.30930.
4
Neutrophil-to-lymphocyte ratio after four weeks of nivolumab administration as a predictive marker in patients with pretreated non-small-cell lung cancer.纳武利尤单抗治疗 4 周后的中性粒细胞与淋巴细胞比值可作为预处理非小细胞肺癌患者的预测标志物。
Thorac Cancer. 2018 Oct;9(10):1291-1299. doi: 10.1111/1759-7714.12838. Epub 2018 Aug 20.
5
Abscopal Effect of Nivolumab in a Patient with Primary Lung Cancer.纳武单抗在一名原发性肺癌患者中的远隔效应
J Thorac Oncol. 2017 Sep;12(9):e143-e144. doi: 10.1016/j.jtho.2017.05.004.
6
Clinical impact of post-progression survival on overall survival in patients receiving nivolumab monotherapy as a second-line treatment for advanced non-small cell lung cancer.纳武利尤单抗单药二线治疗晚期非小细胞肺癌患者的后进展生存期对总生存期的临床影响。
Thorac Cancer. 2021 Apr;12(8):1171-1179. doi: 10.1111/1759-7714.13886. Epub 2021 Feb 24.
7
Predictive Performance of Four Programmed Cell Death Ligand 1 Assay Systems on Nivolumab Response in Previously Treated Patients with Non-Small Cell Lung Cancer.四种程序性死亡配体 1 检测系统在先前治疗的非小细胞肺癌患者对纳武利尤单抗反应中的预测性能。
J Thorac Oncol. 2018 Mar;13(3):377-386. doi: 10.1016/j.jtho.2017.11.123. Epub 2017 Dec 9.
8
Long-lasting responses after discontinuation of nivolumab treatment for reasons other than tumor progression in patients with previously treated, advanced non-small cell lung cancer.在先前接受过治疗的晚期非小细胞肺癌患者中，因肿瘤进展以外的原因停用纳武利尤单抗治疗后出现的长期反应。
Cancer Commun (Lond). 2019 Nov 21;39(1):78. doi: 10.1186/s40880-019-0423-3.
9
Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non-Small Cell Lung Cancer Patients.连续肌钙蛋白检测用于早期发现晚期非小细胞肺癌患者纳武利尤单抗相关心脏毒性
Oncologist. 2018 Aug;23(8):936-942. doi: 10.1634/theoncologist.2017-0452. Epub 2018 Mar 22.
10
Comparable outcomes of nivolumab in patients with advanced NSCLC presenting with or without brain metastases: a retrospective cohort study.纳武利尤单抗治疗伴或不伴脑转移的晚期 NSCLC 患者的可比结局：一项回顾性队列研究。
Cancer Immunol Immunother. 2020 Mar;69(3):399-405. doi: 10.1007/s00262-019-02462-1. Epub 2020 Jan 6.

引用本文的文献

1
5-HT orchestrates histone serotonylation and citrullination to drive neutrophil extracellular traps and liver metastasis.5-羟色胺协调组蛋白5-羟色胺化和瓜氨酸化以驱动中性粒细胞胞外陷阱形成和肝转移。
J Clin Invest. 2025 Feb 4;135(8). doi: 10.1172/JCI183544. eCollection 2025 Apr 15.
2
Treatment Options for Patients with Non-Small Cell Lung Cancer and Liver Metastases.非小细胞肺癌伴肝转移患者的治疗选择
Curr Issues Mol Biol. 2024 Nov 24;46(12):13443-13455. doi: 10.3390/cimb46120802.
3
The role of SIRT1 in autophagy and drug resistance: unveiling new targets and potential biomarkers in cancer therapy.
SIRT1在自噬和耐药性中的作用：揭示癌症治疗中的新靶点和潜在生物标志物。
Front Pharmacol. 2024 Sep 30;15:1469830. doi: 10.3389/fphar.2024.1469830. eCollection 2024.
4
Molecular features of NSCLC patients with liver metastasis.非小细胞肺癌肝转移患者的分子特征。
Ther Adv Med Oncol. 2024 Sep 24;16:17588359241275421. doi: 10.1177/17588359241275421. eCollection 2024.
5
Patterns of failure and the subsequent treatment after progression on first-line immunotherapy monotherapy in advanced non-small cell lung cancer: a retrospective study.一线免疫单药治疗后进展的晚期非小细胞肺癌的失败模式和后续治疗：一项回顾性研究。
BMC Cancer. 2024 Sep 27;24(1):1190. doi: 10.1186/s12885-024-12888-1.
6
The Efficiency and Safety of Triple-Drug Combination of Albumin-Bound Paclitaxel, Anlotinib and PD-1/L1 Inhibitors in the 2 or Above Line of Advanced NSCLC: A Retrospective Cohort Study.白蛋白结合型紫杉醇、安罗替尼和PD-1/L1抑制剂三联药物组合用于晚期非小细胞肺癌二线及以上治疗的有效性和安全性：一项回顾性队列研究
Cancer Manag Res. 2024 Aug 8;16:1003-1012. doi: 10.2147/CMAR.S472196. eCollection 2024.
7
Construction of a nomogram model based on biomarkers for liver metastasis in non-small cell lung cancer.基于生物标志物构建非小细胞肺癌肝转移的列线图模型。
Thorac Cancer. 2024 Sep;15(26):1897-1911. doi: 10.1111/1759-7714.15417. Epub 2024 Aug 4.
8
Real‑world evidence of advanced non‑small cell lung carcinoma treated with an immune checkpoint inhibitor plus chemotherapy.免疫检查点抑制剂联合化疗治疗晚期非小细胞肺癌的真实世界证据
Oncol Lett. 2024 Jun 27;28(3):405. doi: 10.3892/ol.2024.14538. eCollection 2024 Sep.
9
Two nomograms constructed for predicting the efficacy and prognosis of advanced non‑small cell lung cancer patients treated with anti‑PD‑1 inhibitors based on the absolute counts of lymphocyte subsets.基于淋巴细胞亚群绝对计数构建的预测抗 PD-1 抑制剂治疗晚期非小细胞肺癌患者疗效和预后的两个列线图。
Cancer Immunol Immunother. 2024 Jun 4;73(8):152. doi: 10.1007/s00262-024-03738-x.
10
Poor efficacy of immune checkpoint inhibitor treatment in advanced thymic carcinoma patients with liver metastases.免疫检查点抑制剂治疗对伴有肝转移的晚期胸腺癌患者疗效不佳。
Ther Adv Med Oncol. 2024 May 28;16:17588359241253127. doi: 10.1177/17588359241253127. eCollection 2024.